Goldman Sachs’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.32M | Sell |
1,297,982
-704,979
| -35% | -$4.52M | ﹤0.01% | 2404 |
|
|
2025
Q1 | $7.09M | Buy |
2,002,961
+143,065
| +8% | +$506K | ﹤0.01% | 2483 |
|
|
2024
Q4 | $7.03M | Buy |
1,859,896
+246,033
| +15% | +$930K | ﹤0.01% | 2595 |
|
|
2024
Q3 | $5.23M | Sell |
1,613,863
-996,557
| -38% | -$3.23M | ﹤0.01% | 2727 |
|
|
2024
Q2 | $4.96M | Sell |
2,610,420
-332,766
| -11% | -$632K | ﹤0.01% | 2613 |
|
|
2024
Q1 | $8.36M | Buy |
2,943,186
+1,686,325
| +134% | +$4.79M | ﹤0.01% | 2194 |
|
|
2023
Q4 | $18.5M | Buy |
1,256,861
+69,733
| +6% | +$1.03M | ﹤0.01% | 1633 |
|
|
2023
Q3 | $21.7M | Sell |
1,187,128
-163,350
| -12% | -$2.99M | ﹤0.01% | 1444 |
|
|
2023
Q2 | $29.1M | Sell |
1,350,478
-15,694
| -1% | -$339K | 0.01% | 1287 |
|
|
2023
Q1 | $40.1M | Buy |
1,366,172
+329,902
| +32% | +$9.68M | 0.01% | 1049 |
|
|
2022
Q4 | $38.3M | Buy |
1,036,270
+656,871
| +173% | +$24.3M | 0.01% | 1142 |
|
|
2022
Q3 | $10.7M | Buy |
+379,399
| New | +$10.7M | ﹤0.01% | 2073 |
|